"The US Food and Drug Administration's (FDA's) Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee voted yesterday to recommend premarket approval of the Cartiva Synthetic Cartilage Implant for use in pati"...
Monovisc Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Monovisc (high molecular weight hyaluronan injection) is a complex sugar used to treat pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen). Common side effects of Monovisc include joint pain and swelling, injection site reactions, rash, headache, dizziness, chills, hives, itching, nausea, muscle cramps, swelling of legs and feet, and a general feeling of being unwell (malaise).
Monovisc is supplied in a single-use 5 mL syringe containing a 4 mL dose of treatment. Monovisc may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Monovisc should only be administered if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Monovisc (high molecular weight hyaluronan injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Monovisc FDA Prescribing Information: Side Effects
Potential Adverse Effects Of The Device On Health
Reported Device-Related Adverse Events
The most common reported adverse events associated with Monovisc™ are the following:
- Joint swelling
- Injection site pain
Incidences of rash, headache, dizziness, chills, hives, itching, nausea, muscle cramps, peripheral edema, and malaise have also been reported in association with intra-articular injections.
A complete listing of the frequency and rate of adverse events identified in the clinical studies is provided in the Safety section.
Read the entire FDA prescribing information for Monovisc (High Molecular Weight Hyaluronan Injection)
Additional Monovisc Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options